Diagnostic markers of yersiniosis in patients with inflammatory bowel diseases

Relevance. This study is related to the study of the etiology, pathogenesis and clinic of inflammatory bowel diseases (IBD). In a number of patients with IBD who are refractory to anti-inflammatory/immunosuppressive therapy, there are signs of current or transferred yersiniosis infection, not diagnosed by routine methods.

Aim. According to the scientific literature and the results of our own research, to identify the presence and assess the nature of the influence of yersinia on the occurrence and development of IBD.

Materials Methods. In our study, we conducted a bacteriological examination of feces by polymerase chain reaction (PCR) in patients with a diagnosis of IBD (UC and CD) in the acute phase (MMDAI ≥ 4 points for UC and Best index ≥ 150 points for CD), as well as immunological diagnostics using enzyme immunoassay (IFA) in the version of line-blotting (IB). Using the results obtained, clinical and instrumental semiotics were evaluated in subgroups of individuals suffering from IBD with confirmed yersiniosis ("IBD+ IER+") and without it ("IBC+ IER–"). We also assessed the role of intestinal infection by determining the effectiveness of initial antibacterial therapy in the treatment of exacerbation of IBD.

Results. A significant part (in the case of our sample – 45%) of patients with IBD, when examined by high-tech methods, demonstrate the presence of markers of a transferred or current yersiniosis infection. Its role in the initiation and development of autoimmune intestinal inflammatory process requires further clarification.

Conclusions. In 45% of patients with IBD, high-precision examination reveals markers of transferred or current yersiniosis infection. Routine clinical methods for the diagnosis of yersiniosis have low sensitivity and do not allow us to convincingly assess the role of this bacterial agent as a trigger factor for the onset or recurrence of IBD. There is a tendency for greater manifestation in the debut of IBD in patients with markers of systemic yersiniosis. The fact of improvement against the background of empirical antibacterial therapy in 24% of patients with IBD, achievement of early clinical remission in 57% of patients receiving antibiotic therapy, indicates a significant role of bacterial enterocolopathogens in the genesis of chronic intestinal inflammation in a number of patients.

1. Avanduk К. Gastroenterologiya. Moscow. Praktika; 2013. (In Russ).

2. Nikonov EL, Aksyonov VA, Skvortsova TA, et al. Immunotherapy for Inflammatory Bowel Disease. Doctor.Ru. 2019;10(165):31–7. (in Russ). doi:10.31550/1727-2378-2019-165-10-31-37

3. Fedulova EN, Tutina OA, Fedorova OV, et al. Yazvennyy kolit i bolezn’ Krona u detey: novyye podkhody k lecheniyu. Meditsinskiy al’manakh. 2008;(5):160–3. (In Russ).

4. Bonovas S, Nikolopoulos GK, Lytras T, et al. Comparative safety of systemic and low-bioavailability steroids in inflammatory bowel disease: Systematic review and network meta-analysis. Br. J. Clin. Pharmacol. 2018;84(2):239–51. doi:10.1111/bcp.1345

5. Bakulin IG, Skalinskaya MI, Maev IV, et al. Pharmacotherapy of inflammatory bowel diseases: efficacy performance and safety management. Terapevticheskii Arkhiv (Ter. Arkh.). (In Russ). 2021;93(8):841–852. doi:10.26442/00403660.2021.08.200982

6. Turner D, Ruemmele FM, Orlanski-Meyer E, et al. Part 2: Acute Severe Colitis-An Evidence-based Consensus Guideline From the European Crohn’s and Colitis Organization and the European Society of Paediatric Gastroenterology, Hepatology and Nutrition. J. Pediatr. Gastroenterol. Nutr. 2018;67(2):292–310. doi:10.1097/MPG.0000000000002036

7. Belousova YeA. Yazvennyy kolit i bolezn’ Krona. Tver’: Triada; 2002. (In Russ).

8. Maev IV, Shelygin YuA, Skalinskaya MI, et al. The Pathomorphosis of Inflammatory Bowel Diseases. Annals of the Russian Academy of Medical Sciences. 2020;75(1):27–35. (In Russ). doi:10.15690/vramn1219

9. Shapina MV, Khalif IL Use of 5-aminosalicylic acid for treatment of ulcerative colitis in different dosage modes. Meditsinskiy sovet = Medical Council. 2017;(15):44–50. (In Russ). doi.org/10.21518/2079-701X-2017-15-44-50

10. Shchukina OB Preparaty 5-ASK v terapii vospalitel’nykh zabolevaniy kishechnika. Effektivnaya farmakoterapiya. 2010;(6):16–23. (In Russ).

11. Volynets GV, Khavkin AI Inflammatory bowel disease and drug-induced liver damage. Experimental and Clinical Gastroenterology. 2021;(10):138–146. (In Russ). doi.org/10.31146/1682-8658-ecg-194-10-138-146

12. Khalif IL, Nanaeva BA, Golovenko AO, et al. Long-term results of medical treatment in patients with a severe attack of ulcerative colitis. Terapevticheskii Arkhiv (Ter. Arkh.). (In Russ). 2015;87(2):34–8. doi.org/10.17116/terarkh201587234-38

13. Ardizzone S, Maconi G, Russo A, et al. Randomised controlled trial of azathioprine and 5-aminosalicylic acid for treatment of steroid dependent ulcerative colitis. Gut. 2006;55(1):47–53. doi.org/10.1136/gut.2005.068809.

14. Faubion WA, Loftus EV, Harmsen WS, et al. The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study. Gastroenterology. 2001;121(2):255–60. doi.org/10.1053/gast.2001.26279.

15. Yoon JY, Cheon JH, Park JJ, et al. Clinical outcomes and factors for response prediction after the first course of corticosteroid therapy in patients with active ulcerative colitis. J. Gastroenterol Hepatol. 2011;26(7):1114–22. doi:10.1111/j.1440- 1746.2011.06688.x.

16. Munkholm P, Langholz E, Davidsen M, et al. Frequency of glucocorticoid resistance and dependency in Crohn’s disease. Gut. 1994;35(3):360–2.

17. Wei B, Huang T, Dalwadi H, et al. Pseudomonas fluorescens Encodes the Crohn’s Disease-Associated 12 Sequence and T-Cell Superantigen. Infect Immun. 2002;70(12):6567–75. doi:10.1128/IAI.70.12.6567-6575.2002.

18. Rhodes JM. The role of Escherichia coli in inflammatory bowel disease. Gut. 2007;56(5):610–2. doi:10.1136/gut.2006.111872.

19. Payne M, Girdwood AH, Roost RW, et al. Yersinia enterocolitica and Crohn’s disease. A case report. S Afr Med J. 1987;72(1):53–5.

20. De Berardis B, Torresini G, Brucchi M, et al. Yersinia enterocolitica intestinal infection with ileum perforation: report of a clinical observation. Acta Biomed. 2004;75(1):77–81.

21. Van Vliet MJ, Harmsen HJ, de Bont ES, et al. The role of intestinal microbiota in the development and severity of chemotherapy-induced mucositis. PLoS Pathog. 2010;6(5):e1000879. doi:10.1371/journal.ppat.1000879.

22. Nazarov V.E, Voskresenskaya E.A., Tseneva G.Ya., Kokorina G.I., Bogumilchik E.A. Yersinioses – new «therapeutic» infections in gastroenterological practice? Klinicheskie perspektivy gastrojenterologii, gepatologii 2015; (6):16–24. (In Russ.).

23. Sagynbaeva VE, Golovanova EV, Lazebnik LB, et al. Yersiniosis - the reason for the development of extraintestinal inflammatory bowel disease, or symptom of reactivation of opportunistic infections against the background of biological therapy? Experimental and Clinical Gastroenterology. 2018;(5):78–85. (In Russ).

24. Ivashkin VT, Shelygin YuA, Abdulganiyeva DI, et al. Guidelines of the Russian gastroenterological association and Russian Association of Coloproctology on diagnostics and treatment of ulcerative colitis in adults. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2015;16(1):48–65. (In Russ)